Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study. Read more about Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study.
Phase II TPDCV protocol for pediatric low-grade hypothalamic/chiasmatic gliomas: 15-year update. Read more about Phase II TPDCV protocol for pediatric low-grade hypothalamic/chiasmatic gliomas: 15-year update.
High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. Read more about High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer.
Spontaneous canine gliomas: overexpression of EGFR, PDGFRalpha and IGFBP2 demonstrated by tissue microarray immunophenotyping. Read more about Spontaneous canine gliomas: overexpression of EGFR, PDGFRalpha and IGFBP2 demonstrated by tissue microarray immunophenotyping.
High-dose chemotherapy and autologous stem cell rescue for atypical teratoid/rhabdoid tumor of the central nervous system. Read more about High-dose chemotherapy and autologous stem cell rescue for atypical teratoid/rhabdoid tumor of the central nervous system.
Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival. Read more about Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival.
Primary gliosarcoma: key clinical and pathologic distinctions from glioblastoma with implications as a unique oncologic entity. Read more about Primary gliosarcoma: key clinical and pathologic distinctions from glioblastoma with implications as a unique oncologic entity.
A human brainstem glioma xenograft model enabled for bioluminescence imaging. Read more about A human brainstem glioma xenograft model enabled for bioluminescence imaging.
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. Read more about Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.
